Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study.
about
Pharmacological interventions for treating dyslipidemia in patients with HIV infectionRole of PD-1 in HIV pathogenesis and as target for therapySTART or SMART? Timing of Antiretroviral Therapy Initiation and Cardiovascular Risk for People With Human Immunodeficiency Virus InfectionCardiovascular disease in human immunodeficiency virus infected patients: A true or perceived risk?HIV infection and older Americans: the public health perspectiveHIV infection and the risk of acute myocardial infarction.Cardiovascular Complications of HIV-Associated Immune DysfunctionThe end of AIDS: HIV infection as a chronic diseaseAgeing and inflammation in patients with HIV infection.Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort.An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study.Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE-NL) and Data Collection on Adverse Events ofInitiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease?Microbial translocation and cardiometabolic risk factors in HIV infection.Prevalence and risk factors of poor immune recovery among adult HIV patients attending care and treatment centre in northwestern Tanzania following the use of highly active antiretroviral therapy: a retrospective study.Prevalence and Risk Factors of Mortality among Adult HIV Patients Initiating ART in Rural Setting of HIV Care and Treatment Services in North Western Tanzania: A Retrospective Cohort StudyReclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals.Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial.Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database.Hypertension and obesity as cardiovascular risk factors among HIV seropositive patients in Western KenyaEpidemiology of coronary heart disease in patients with human immunodeficiency virusResidual immune dysregulation syndrome in treated HIV infection.T-cell activation, both pre- and post-HAART levels, correlates with carotid artery stiffness over 6.5 years among HIV-infected women in the WIHSCost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda.Mortality and immunological recovery among older adults on antiretroviral therapy at a large urban HIV clinic in Kampala, Uganda.Elevated rates of intracerebral hemorrhage in individuals from a US clinical care HIV cohort.Immunologic basis of cardiovascular disease in HIV-infected adults.Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era.Immune dysregulation and vascular risk in HIV-infected patients: implications for clinical care.The immunological and virological consequences of planned treatment interruptions in children with HIV infection.Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study.Cardiovascular disease risk in an aging HIV population: not just a question of biology.Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: the IMMUNEF clinical trialHypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution.Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapyProgression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohortEpidemiology and management of antiretroviral-associated cardiovascular disease.Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patientsEvaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy.Nutritional and metabolic correlates of cardiovascular and bone disease in HIV-infected patients.
P2860
Q24236121-1EB23658-59AD-43C1-942A-39D02730531BQ24634293-DE3347A3-2CB6-4CD8-9B58-15F5E16AA5D8Q26753830-004904BF-5C3A-4821-BB2F-3EBD03190B90Q26777866-3ECD985F-E4B9-427E-8D44-61426D013377Q26858824-9C3D32FF-E7A8-4E9E-A945-144403EF56E2Q27347231-75ECE00A-18C6-4C76-8497-0C2177F1BF74Q28084981-9453CBBF-FAE5-4CAD-8856-E39A2BDA783CQ28300749-B539FAA0-3255-41A6-8FB5-CCB7F175758FQ30244296-1E1E7398-BB48-428D-BE15-B0B02BB94809Q30593046-27C40C1D-7160-420A-A787-95A9AE0DC48EQ30934548-8244E18C-BCD1-4306-A332-53F4F821FE64Q30987054-FDFA1A55-8310-4E3D-952A-E4A202DA930FQ33649200-10278F66-7F65-4B33-BC84-120C03AA2AF8Q33713895-C65749BB-0EB7-4F5C-BD52-3D2A60CAECCDQ33781469-35DCE9CA-6F6B-430B-B6CE-CD17DB6FFAA7Q33862338-8ACF29B4-03C3-453B-945E-17C6BF708EC5Q33917180-1617397B-DB43-40AD-9B57-7382AAA06AE8Q33919900-4747374A-E8A6-4232-812E-7DEB1A7B3D43Q33933071-B31BEA8F-0ADA-4628-A117-40EF21595A47Q33968354-914C50F4-0E62-45B1-9BAE-7A7AC953FE3BQ33998067-C5B9CD74-1F73-4FD5-A009-FDEB74B9EFA5Q34020121-7F3EF5DC-FD9B-4F13-8BD1-F03697CE8A20Q34342183-9884B4B6-E28C-4E19-B39F-2D698CE68583Q34401635-00935DFE-EAF7-42E3-9E9C-D91AD29F10B1Q34443404-3C861395-0807-42BF-B6D0-07506730D227Q34553819-34BDAD51-FA86-4D80-9FA4-353E62DEC0C6Q34638205-A1613D86-C3EA-4217-B472-6126275286BBQ34663606-24EA44EB-4140-4636-A8BB-1A765EA19EA2Q34764372-B70F1E7C-A89C-48FA-9728-6387C5F06830Q35032305-14FF62D7-8438-4542-BE42-F16D76D68783Q35034083-A29C1301-74F7-4000-8AE4-B0F2FAF340B3Q35064091-03CC5CCC-29D0-4984-9878-C02CC900AC82Q35074381-6D33F865-7D08-4C20-95CD-ECF2F98CEAA4Q35176441-01E4BEE3-CC75-41B9-B8BB-C9B46C8EDC68Q35190397-5704AB32-544C-47B0-BA45-E578F8BCD7CBQ35215672-4FA296E4-464A-4F1C-9350-570358AE7C26Q35338096-038F32EA-C4CC-4DFE-AA24-8C12CB0B4BE1Q35465943-9BCA98AD-B7F5-45EA-8565-9EB07461D3B6Q35560802-8F7C5AB5-77B8-4B26-86FE-99C30CAAF6FFQ35578707-5F93C513-1C3E-48D2-99A8-23168B52AB16
P2860
Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Low CD4+ T cell count is a ris ...... s in the HIV outpatient study.
@en
Low CD4+ T cell count is a ris ...... s in the HIV outpatient study.
@nl
type
label
Low CD4+ T cell count is a ris ...... s in the HIV outpatient study.
@en
Low CD4+ T cell count is a ris ...... s in the HIV outpatient study.
@nl
prefLabel
Low CD4+ T cell count is a ris ...... s in the HIV outpatient study.
@en
Low CD4+ T cell count is a ris ...... s in the HIV outpatient study.
@nl
P2093
P356
P1476
Low CD4+ T cell count is a ris ...... s in the HIV outpatient study.
@en
P2093
Carl Armon
E M Tedaldi
HIV Outpatient Study (HOPS) Investigators
Joan S Chmiel
John T Brooks
Kate Buchacz
Kathy Wood
Kenneth A Lichtenstein
Kern Buckner
Scott D Holmberg
P304
P356
10.1086/655144
P407
P577
2010-08-01T00:00:00Z